Lymphopenia is one of the characteristic features of COVID-19 disease in adults, and a predictor of morbidity and mortality [@b0005], [@b0010]. Patients with lymphopenia have more severe disease; correction of lymphopenia correlates with recovery from severe disease, while severe and sustained lymphopenia is associated with fatal outcomes [@b0005], [@b0010]. Consistent with higher mortality in adults with COVID-19, lymphopenia is more common in adults than children. In meta-analyses, 15% of the 1667 children, and over 50% of the 3,062 adults had lymphopenia [@b0015], [@b0020]. Lymphopenia was also observed in 46% of the 80 children, and about 70% of 138 adults in SARS-CoV 2003 infection, and lymphopenia was reported to persist for as long as 1 to 2 years [@b0025], [@b0030], [@b0035].

The mechanisms underlying lymphopenia during SARS-CoV and SARS-CoV-2 infections remain unclear. Lymphocytes have minimal expression of angiotensin converting enzyme 2 (ACE2) [@b0040], [@b0045]. SARS-CoV and SARS-CoV-2 have not been demonstrated to directly infect lymphocytes [@b0045]. Peripheral T lymphocytes, both CD4+ and CD8+, are rapidly reduced in acute SARS-CoV infection possibly due to lymphocytic infiltration and sequestration in specific target organs [@b0050]. Lymphopenia, in the later stages of COVID-19 illness, may have been mediated by thymic involution and atrophy induced by hyperinflammation and cytokine release comprising of IL-6, TNF-α, and IL-1 [@b0055]. However, lymphopenia has been reported to occur concurrently with the onset of clinical symptoms in COVID-19 [@b0005]. We postulate that lymphopenia observed at the onset or during the early stages of COVID-19 illness is caused by increased generation of prostaglandin D~2~ by the respiratory epithelium.

Prostaglandin D~2~ (PGD~2~) is a key eicosanoid generated in respiratory infections. Severe bronchiolitis in infants caused by respiratory syncytial virus (RSV) leads to marked increase in PGD~2~ in the airways [@b0060]. Mice infected with SARS-CoV also exhibit significant increases in PGD~2~ concentrations in the bronchoalveolar lavage fluid [@b0065]. SARS-CoV respiratory infection stimulates PGD~2~ production by increased expression of phospholipase A~2~ group IID (PLA~2~G2D), cyclooxygenase-2 (COX-2), and hematopoietic PGD~2~ synthase (hPGDS) [@b0070]. Furthermore, protein sequences in the spike and nucleocapsid proteins of SARS-CoV activate the expression of the COX-2 gene [@b0075], [@b0080]. Increased expression of PLA~2~G2D and hPGDS genes also occurs with aging, leading to increased levels of PGD~2~ in the airways of the elderly [@b0065]. Compared to the 6-week old mice, there is a 300--400% increase in the airways' PGD~2~ levels in 12-month old and 22-month old mice [@b0065]. PGD~2~ action is mediated by binding to two G-protein coupled receptors, D-prostanoid receptor 1 (DP~1~); and D-prostanoid receptor 2 (DP~2~), formerly known as chemoattractant receptor-homologous molecule on T helper type 2 cells (CRTH2) [@b0085]. PGD~2~ has been reported to affect the host's innate and adaptive immune responses to viruses including SARS-CoV as described below.

Early in infection, activated respiratory dendritic cells (rDC) undergo a maturation process that includes upregulation of costimulatory ligands, antigen-presenting complexes, and importantly, chemokine receptors such as C--C chemokine receptor type 7 (CCR7) [@b0065]. The elevated levels of chemokine receptors facilitate migration of antigen-bearing rDCs to the local draining lymph nodes (DLNs) in the mediastinum where they participate in initiating adaptive host immune response to the respiratory virus. PGD~2~/DP~1~ signaling in the airway epithelial cells leads to the inhibition of CCR7 which suppresses rDC migration to draining lymph nodes. This leads to impairment of T lymphocyte priming and maturation, thereby leading to lymphopenia [@b0065], [@b0090]. Second, PGD~2~/DP~2~ signaling stimulates Group 2 innate lymphoid cells (ILC2) and T helper 2 (Th2) cells to secrete interleukin-13 (IL-13). IL-13 upregulates monocyte-macrophage derived suppressor cells (MDSC), which downregulates the T-lymphocyte response, causing lymphopenia [@b0095], [@b0100], [@b0105]. MDSCs mediated impairment of pathogen specific adaptive immune responses has been demonstrated with *Hemophilus influenzae* respiratory infection [@b0110]. Interestingly, ILC2, despite their scarcity, are the dominant innate lymphoid cell population in the lung, indicating a key role as first responders and amplifiers upon immune challenge at this site [@b0115].

Based on the above findings, we hypothesize that an increase in airway PGD~2~ levels initiates lymphopenia in COVID-19 ([Fig. 1](#f0005){ref-type="fig"} ). We propose that antagonism of PGD~2~ synthesis or signaling can prevent lymphopenia or promote recovery of lymphocyte counts in COVID-19 disease. However, suppression of PGD~2~ synthesis will inhibit PGD~2~/DP~1~ signaling which has been demonstrated to attenuate inflammation and reduce vascular permeability [@b0120], [@b0125]. Therefore, selective targeting of PGD~2~/DP~2~ signaling, while sparing PGD~2~/DP~1~ axis, is necessary to restore immune dysfunction during the symptomatic phase of COVID-19. Ramatroban is a potent, reversible, and selective antagonist of PGD~2~/DP~2~ receptors that has been shown to inhibit PGD~2~ stimulated IL-13 secretion, with an IC-50 of 118 nM [@b0085], [@b0100]. Ramatroban has been used orally as a treatment for allergic rhinitis in Japan for the past 20 years.[@b0130] Given the global disease burden of the COVID-19 pandemic, there is an urgent need to examine the role of eicosanoids including PGD~2~ in the pathogenesis of the disease, and to investigate the potential immunotherapeutic role of PGD~2~ antagonists such as ramatroban.Fig. 1Proposed mechanism of lymphopenia in patients with COVID-19. A host specific, exuberant PGD~2~ response early in infection, initiates DP~1~ signaling, which inhibits the dendritic cell function by downregulating CCR7, leading to a weak T cell response. PGD~2~/DP~2~ signaling stimulates respiratory ILC2 and Th2 cells, which secrete IL-13. IL-13 stimulates proliferation of MDSC cells, thereby downregulating the pathogen specific T cell responses. Excessive PGD~2~ action via DP~1~ receptors during the incubation period and DP~2~ receptors during the symptomatic stage leads to lymphopenia. Lymphopenia is a predictor of morbidity and mortality in COVID-19.
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